Research &
Collaborations
Advancing Discovery Through Epitope-Level Precision
We map antibody responses to identify disease biomarkers with research partners worldwide.
Why Partner With Biotome?
Genuine Collaboration
We write grants with you. Our team contributes to study design, provides preliminary data, and assists with making your proposals competitive.
Scientific Depth, Commercial Capability
We bring discovery expertise and know-how to translate findings into clinical tools. From epitope mapping through prototype validation.
Improving Health Care for All
We target diseases affecting underserved populations where early detection and low-cost diagnostics can drive meaningful impact.
IP Potential
Peptide epitopes are patentable, proteins aren't. Let our experience with patents and IP strategy assist your project towards licensing or the next great venture.
Idiopathic Pulmonary Fibrosis: Finding the Autoimmune Subset
with the Institute for Respiratory Health, University of WA
IPF patients with autoantibody responses may benefit from immunosuppression rather than standard antifibrotic therapy. We're validating autoantigen targets from PhIPseq analysis using peptide microarrays and testing antibody responses across multiple isotypes. Working from 30 human proteins, we've identified markers that distinguish the autoimmune phenotype in IPF patients.
We will be optimizing 10-20 peptide markers for a clinical ELISA that could stratify IPF patients or provide early diagnosis. This test could be the basis of future treatment decisions: immunosuppression for autoimmune-driven cases, and antifibrotics for others.
Rheumatic Heart Disease: From Strep A to Prevention
with The Kids Institute
RHD kills 300,000 annually, mostly children in poor settings. We're mapping antibody responses to the entire Strep A proteome to distinguish protective immunity from harmful cross-reactivity. Using unique samples from controlled human challenge studies and natural paediatric infections, we identify critical epitopes that discriminate disease, correlate with protection, and indicate disease progression.
Beyond discovery, we have prototyped a serology diagnostic to discriminate RHD from healthy individuals using peptide targets.
Multiple Sclerosis: Decoding the EBV Connection
with the Perron Institute
We're identifying EBV-specific antibody signatures in clinically isolated syndrome (CIS), the first clinical sign of MS. Our epitope mapping complements Perron's T cell studies, providing the B cell response picture while they characterize CD8+ T cells in MS brain lesions.
By testing sequences from EBV variants and human proteins, we're finding which epitopes correlate with disease onset.
We hope to address why EBV is present in 99% of MS patients yet most infected individuals never develop the disease. The targets will contribute to diagnostic tools for CIS patients while contributing to understanding of MS pathogenesis.